Polyserp Therapeutics

Polyserp Therapeutics is a preclinical-stage biotechnology company focused on developing innovative treatments for Alpha-1 Antitrypsin Deficiency (AATD) and other inflammatory diseases. The company utilizes a proprietary platform to engineer recombinant serpins (serine protease inhibitors) with improved pharmacological properties, such as increased potency and extended half-life. Their lead programs aim to provide more effective alternatives to current plasma-derived augmentation therapies for patients with lung and liver manifestations of AATD. Polyserp's technology is based on research into protein folding and protease inhibition to address significant unmet needs in respiratory health. The company is a spin-out from the University of Florida, leveraging decades of clinical and scientific expertise in serpin biology.